Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Tryptophan-kynurenine metabolism and insulin resistance in hepatitis C patients.

Oxenkrug GF, Turski WA, Zgrajka W, Weinstock JV, Summergrad P.

Hepat Res Treat. 2013;2013:149247. doi: 10.1155/2013/149247. Epub 2013 Sep 4.

2.

Effects of PEG-interferon alpha plus ribavirin on tryptophan metabolism in patients with chronic hepatitis C.

Comai S, Cavalletto L, Chemello L, Bernardinello E, Ragazzi E, Costa CV, Bertazzo A.

Pharmacol Res. 2011 Jan;63(1):85-92. doi: 10.1016/j.phrs.2010.10.009. Epub 2010 Oct 19.

PMID:
20940053
3.

Insulin resistance and dysregulation of tryptophan-kynurenine and kynurenine-nicotinamide adenine dinucleotide metabolic pathways.

Oxenkrug G.

Mol Neurobiol. 2013 Oct;48(2):294-301. doi: 10.1007/s12035-013-8497-4. Epub 2013 Jun 28. Review.

4.

[Impact of interferon alpha immunotherapy on tryptophan metabolism in patients with chronic hepatitis C. Results of a pilot studies on ten patients].

Vignau J, Costisella O, Canva V, Imbenotte M, Duhamel A, Lhermitte M.

Encephale. 2009 Oct;35(5):477-83. doi: 10.1016/j.encep.2007.09.007. Epub 2008 Jun 12. French.

PMID:
19853722
5.

Disturbances of Tryptophan Metabolism and Risk of Depression in HCV Patients Treated with IFN-Alpha.

Oxenkrug G, Turski W, Zgrajka W, Weinstock J, Ruthazer R, Summergrad P.

J Infect Dis Ther. 2014 Feb 25;2(2). pii: 131.

6.

Tryptophan Breakdown in Patients with HCV Infection is Influenced by IL28B Polymorphism.

Zoller H, Jenal A, Staettermayer AF, Schroecksnadel S, Ferenci P, Fuchs D.

Pharmaceuticals (Basel). 2015 Jun 18;8(2):337-50. doi: 10.3390/ph8020337.

7.

IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity.

Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpé S, Maes M.

Mol Psychiatry. 2005 Jun;10(6):538-44.

PMID:
15494706
8.

CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression.

Raison CL, Dantzer R, Kelley KW, Lawson MA, Woolwine BJ, Vogt G, Spivey JR, Saito K, Miller AH.

Mol Psychiatry. 2010 Apr;15(4):393-403. doi: 10.1038/mp.2009.116. Epub 2009 Nov 17.

9.

Depressive symptoms as a side effect of Interferon-α therapy induced by induction of indoleamine 2,3-dioxygenase 1.

Murakami Y, Ishibashi T, Tomita E, Imamura Y, Tashiro T, Watcharanurak K, Nishikawa M, Takahashi Y, Takakura Y, Mitani S, Fujigaki H, Ohta Y, Kubo H, Mamiya T, Nabeshima T, Kim HC, Yamamoto Y, Saito K.

Sci Rep. 2016 Jul 20;6:29920. doi: 10.1038/srep29920.

10.

Disturbed tryptophan metabolism in cardiovascular disease.

Mangge H, Stelzer I, Reininghaus EZ, Weghuber D, Postolache TT, Fuchs D.

Curr Med Chem. 2014 Jun;21(17):1931-7. Review.

11.

Does tryptophan degradation along the kynurenine pathway mediate the association between pro-inflammatory immune activity and depressive symptoms?

Quak J, Doornbos B, Roest AM, Duivis HE, Vogelzangs N, Nolen WA, Penninx BW, Kema IP, de Jonge P.

Psychoneuroendocrinology. 2014 Jul;45:202-10. doi: 10.1016/j.psyneuen.2014.03.013. Epub 2014 Apr 5.

PMID:
24845191
12.

Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment.

Capuron L, Neurauter G, Musselman DL, Lawson DH, Nemeroff CB, Fuchs D, Miller AH.

Biol Psychiatry. 2003 Nov 1;54(9):906-14.

PMID:
14573318
13.
14.

HCV patients, psychopathology and tryptophan metabolism: analysis of the effects of pegylated interferon plus ribavirin treatment.

Zignego AL, Cozzi A, Carpenedo R, Giannini C, Rosselli M, Biagioli T, Aldinucci A, Laffi G, Moroni F.

Dig Liver Dis. 2007 Sep;39 Suppl 1:S107-11.

PMID:
17936210
15.

Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: A case-control study.

Lecube A, Hernández C, Genescà J, Simó R.

Diabetes Care. 2006 May;29(5):1096-101.

PMID:
16644643
16.

Oxidative tryptophan metabolism in renal allograft recipients: increased kynurenine synthesis is associated with inflammation and OKT3 therapy.

Holmes EW, Russell PM, Kinzler GJ, Reckard CR, Flanigan RC, Thompson KD, Bermes EW Jr.

Cytokine. 1992 May;4(3):205-13.

PMID:
1498255
17.

Accelerated tryptophan degradation predicts poor survival in trauma and sepsis patients.

Ploder M, Spittler A, Kurz K, Neurauter G, Pelinka LE, Roth E, Fuchs D.

Int J Tryptophan Res. 2010;3:61-7. Epub 2010 Jun 10.

18.

Tryptophan catabolism in females with irritable bowel syndrome: relationship to interferon-gamma, severity of symptoms and psychiatric co-morbidity.

Fitzgerald P, Cassidy Eugene M, Clarke G, Scully P, Barry S, Quigley Eamonn MM, Shanahan F, Cryan J, Dinan Timothy G.

Neurogastroenterol Motil. 2008 Dec;20(12):1291-7. doi: 10.1111/j.1365-2982.2008.01195.x. Epub 2008 Sep 24.

PMID:
18823288
19.

Serum tryptophan and kynurenine concentrations as parameters for indoleamine 2,3-dioxygenase activity in patients with endometrial, ovarian, and vulvar cancer.

de Jong RA, Nijman HW, Boezen HM, Volmer M, Ten Hoor KA, Krijnen J, van der Zee AG, Hollema H, Kema IP.

Int J Gynecol Cancer. 2011 Oct;21(7):1320-7. doi: 10.1097/IGC.0b013e31822017fb.

PMID:
21720257
20.

Supplemental Content

Support Center